---

$2.77

-0.1170 ( -4.33% ) 11.9K

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-07-05	Sale	-10000.00	Bernards Rene
2024-07-02	Sale	-10000.00	Brown Regina
2024-07-02	Sale	-10000.00	Forman Stephen J.
2024-07-02	Sale	-10000.00	Yen Yun
2023-10-16	Sale	-250000.00	van der Baan Bastiaan Jeroen
2023-10-05	Buy	10000.00	van der Baan Bastiaan Jeroen
2023-10-04	Buy	4473.00	Bernards Rene
2023-09-27	Sale	-250000.00	van der Baan Bastiaan Jeroen

Reset

Symbol	Issuer Name	Market Value ↓	Share Quantity
No records found.